ZOMEDICA PEDIATRICS stock has surged to record highs as the pharmaceutical industry continues to gain momentum amid a series of high-profile drug trials.ZOMEDICHAN MEDICALS stock is up $5.6 billion, or 13.5%, to $23.60 on the Nasdaq.

It is the latest high for ZOMIDACO, a biotechnology company founded by ex-CEO David Voss in 2006.

The company is focused on developing a novel therapy for patients with cancer.ZOCEDICS has gained a stunning 52% to $13.95 on the stock market, making it the fastest-growing biotech in history.

The biotech company has been developing an anti-inflammatory drug called ZOALX.ZOALEX is a cancer-fighting drug that is already approved in Europe, and is expected to be approved in the United States in the next two years.ZOAIL has been the best performing biotech stock this year, rising 8% to a record high of $21.13 on the New York Stock Exchange.

ZOILLIX has been up 5% to an all-time high of about $27.15 on the NYSE.